SecBot SecBot

ELDN

Eledon Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001404281 Biotech & Drug Discovery
$2.41 +0.20 (+9.05%)
Oct 27 4:00 PM ET · prev $2.21
Market cap
$186.9M
Micro cap
Median target
$8.00
+232% · range $7.00–12.00
Next earnings
Nov 18
in 22 days · EPS est. −$0.19
1 year
−39.4%
from $3.98 · Oct 28
30 days
−8.7%
from $2.64
52-week range
$1.39–4.36
−45% from high · low Nov 20
Avg volume 20D
750.1K
shares / day
Short interest
7.90M
≈9.7% of shares · +0.6%
Days to cover
10.3
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 26 added (0 new), 2 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.185 → −$0.190 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.6% to 7.90M shares. 10.3 days to cover, ≈9.7% of shares.

  • TrendDOWNTREND

    12% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GOLDMAN SACHS GROUP INCDOUBLED2,510,308$9.9M
STATE STREET CORPADD1,621,969$6.4M
UBS Group AGADD1,048,245$4.1M
DIMENSIONAL FUND ADVISORS LPDOUBLED538,738$2.1M
MORGAN STANLEYDOUBLED485,092$1.9M
Brevan Howard Capital Management LPADD304,707$1.2M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED252,232$993.8K
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD247,404$974.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 5 analysts

Price is below the lowest target. Median implies +232%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jul 21, 2026Rodman & Renshaw
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 31, 2026
Gros David-Alexandre C
Chief Executive Officer
TAX W/H$658.4K
Jul 31, 2026
Perrin Steven
President
AWARD152,353 sh
Jul 31, 2026
Gros David-Alexandre C
Chief Executive Officer
AWARD354,454 sh
Jul 31, 2026
Perrin Steven
President
TAX W/H$243.8K

Earnings setup

Estimates
Nov 18
reports in 22 days
−$0.19
EPS estimate, this quarter
−3%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.21–-$0.15+0.0%$0.00
Next Q-$0.16-$0.22–-$0.01+0.0%$0.00
Current FY-$0.93-$1.04–-$0.77+0.0%$0.00
Next FY-$0.77-$0.92–-$0.67+0.0%$0.00

Short side

FINRA· Oct 15, 2026
7,896,950
shares short
+0.6%
vs prior settlement
10.3
days to cover
≈9.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 Routine
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026
Sep 22, 2026 SEC
A strong institutional accumulation cluster emerged in ELDN during Q2 2026, with 26 buyers adding $16.6M in net new…
INST-CLUSTER — Impact 4/10
Sep 22, 2026 Press
Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and presented…
Impact 7/10
Jul 31, 2026 Insider
Gros David-Alexandre C surrendered for taxes 194,791 shares
Chief Executive Officer @ $3.38 ($658.4K)
Jul 31, 2026 Insider
Perrin Steven was granted 152,353 shares
President
Jul 31, 2026 Insider
Gros David-Alexandre C was granted 354,454 shares
Chief Executive Officer
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
2,510,308 shares ($9.9M)
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
1,621,969 shares ($6.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
ELDN Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Oct 5, 2026
Company news
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Sep 22, 2026
FDA
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Aug 31, 2026
Short interest
Short Interest: ELDN up 23% to 7.7M shares
Settlement 2026-08-31 | Days to cover: 8.08 | ≈9.53% of shares outstanding (est.)
Aug 6, 2026
Earnings date
ELDN Q2 2026 Earnings Scheduled — 2026-08-06
Jul 22, 2026
Clinical Trial
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Phase 2 · COMPLETED

SecBot reports

2 filings · 3 press releases · 1 bullish · 0 bearish · 1 neutral
All ELDN filing & press-release reports (5)